A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Inclusion Criteria:

- Men and women, aged 18 or older (except in South Korea, aged 19 or older).

- Histologically confirmed marginal zone lymphoma, including extranodal, nodal, and
splenic subtypes.

- Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined
as the presence of ≥ 1 lesion that measures > 1.5 cm in the longest transverse
diameter and ≥ 1.0 cm in the longest perpendicular diameter.

- Participants with splenic MZL who do not meet the radiographically measurable disease
criteria described herein are eligible for participation provided that bone marrow
infiltration of MZL is histologically confirmed.

- Participants must be willing to undergo an incisional or excisional lymph node or
tissue biopsy or provide a lymph node or tissue biopsy from the most recent available
archival tissue.

- Eastern Cooperative Oncology Group performance status 0 to 2.

Exclusion Criteria:

- Evidence of diffuse large B-cell transformation.

- History of central nervous system lymphoma (either primary or metastatic) or
leptomeningeal disease.

- Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K
inhibitor.

- Allogeneic stem cell transplant within the last 6 months, or autologous stem cell
transplant within the last 3 months before the date of the first dose of study
treatment.

- Active graft versus host disease.

- Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be
eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody
will be eligible if they are negative for HCV-RNA.